IMA203 shows early evidence of response durability
Immatics announced interim results from the phase 1b study of IMA203, PRAME-targeting TCR T therapy, in heavily pretreated PRAME+/HLA-A*02+ solid tumours. With additional patients treated at higher dose levels (DL4 and DL5), 67% cORR looks encouraging (n=9), although expectedly slipping a bit from
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.